Huadong Medicine announced that the clinical trial application for the HDM1005 injection developed by its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. has been approved by the United States Food and Drug Administration, allowing for Phase I clinical trials to be conducted in the USA. HDM1005 injection is a dual-target long-acting agonist of human GLP-1 receptor and GIP receptor peptides, indicated for the treatment of obstructive sleep apnea combined with obesity or overweight patients. The drug's clinical trials in china have been approved by the National Medical Products Administration and are currently undergoing Phase Ia and Ib clinical trials.
- Latest
- Detail
华东医药：HDM1005注射液获美国FDA临床试验批准
Huadong Medicine: HDM1005 injection has received clinical trial approval from the FDA in usa.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
18:49
Caitong Securities: The registration date for interest payment rights of Caitong convertible bonds in 2024 is December 9th.
CAITONG+0.58%
18:45
Peskov: The usa's aid to Ukraine cannot change the situation on the front lines.
18:45
The National Development and Reform Commission's Price Cost and Certification Center held a symposium on the development and running situation of private medical institutions.
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.